Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 834.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -177.81M |
| Shares Out | 49.84M |
| EPS (ttm) | -3.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 686,960 |
| Open | 16.71 |
| Previous Close | 16.17 |
| Day's Range | 16.36 - 17.08 |
| 52-Week Range | 8.24 - 18.38 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 27.00 (+61.19%) |
| Earnings Date | May 8, 2025 |
About MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price forecast is $27.0, which is an increase of 61.19% from the latest price.
News
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clini...
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data re...
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or re...
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday.
Mineralys Therapeutics' blood pressure drug meets goal in trials
Mineralys Therapeutics said on Monday its blood pressure drug, lorundrostat, met the main goal in late- and mid- stage trials.
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by ...
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam ...
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k...
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 t...
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam...
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering t...
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k...
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k...
The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Ther...
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Ther...
The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Ther...
The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Ther...
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Ther...